Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice.

Jagger BW, Dowd KA, Chen RE, Desai P, Foreman B, Burgomaster KE, Himansu S, Kong WP, Graham BS, Pierson TC, Diamond MS.

J Infect Dis. 2019 Jul 1. pii: jiz338. doi: 10.1093/infdis/jiz338. [Epub ahead of print]

PMID:
31260518
2.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

3.

The Many Faces of a Dynamic Virion: Implications of Viral Breathing on Flavivirus Biology and Immunogenicity.

Dowd KA, Pierson TC.

Annu Rev Virol. 2018 Sep 29;5(1):185-207. doi: 10.1146/annurev-virology-092917-043300. Review.

PMID:
30265634
4.

Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome.

Chang AY, Lynch R, Martins K, Encinales L, Cadena Bonfanti AÁ, Pacheco N, Reid SP, Lara Sarabia OE, González Torres HJ, Mejia Castillo S, Barrios Taborda O, Alarcon Gomez M, Guerra Duran B, Martinez Giraldo V, Benitez Ospino A, Porras A, Mendoza AR, Mantus G, Li G, Peng J, Kamalapathy P, Avendaño Echavez LG, Dowd KA, Rengifo-Pardo M, Barraza PP, Jiménez Hernàndez D, González Coba A, De La Hoz Mendoza K, Bethony JM, Simon GL.

Emerg Microbes Infect. 2018 Aug 22;7(1):148. doi: 10.1038/s41426-018-0151-9. No abstract available.

5.

A VSV-based Zika virus vaccine protects mice from lethal challenge.

Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H, Marzi A.

Sci Rep. 2018 Jul 23;8(1):11043. doi: 10.1038/s41598-018-29401-x.

6.

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Frei JC, Wirchnianski AS, Govero J, Vergnolle O, Dowd KA, Pierson TC, Kielian M, Girvin ME, Diamond MS, Lai JR.

J Virol. 2018 Aug 29;92(18). pii: e01023-18. doi: 10.1128/JVI.01023-18. Print 2018 Sep 15.

7.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

8.

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, Muruato AE, Foreman BM, Luo H, Wang T, Barrett AD, Weaver SC, Vasconcelos PFC, Rossi SL, Ciaramella G, Mysorekar IU, Pierson TC, Shi PY, Diamond MS.

Cell. 2017 Jul 13;170(2):273-283.e12. doi: 10.1016/j.cell.2017.06.040.

9.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.016. No abstract available.

10.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 9;168(6):1114-1125.e10. doi: 10.1016/j.cell.2017.02.017. Epub 2017 Feb 17. Erratum in: Cell. 2017 Mar 23;169(1):176.

11.

A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Goo L, VanBlargan LA, Dowd KA, Diamond MS, Pierson TC.

PLoS Pathog. 2017 Feb 16;13(2):e1006178. doi: 10.1371/journal.ppat.1006178. eCollection 2017 Feb.

12.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.

Nature. 2017 Mar 9;543(7644):248-251. doi: 10.1038/nature21428. Epub 2017 Feb 2.

13.

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC.

J Infect Dis. 2016 Nov 15;214(10):1487-1491. Epub 2016 Sep 21.

14.

Rapid development of a DNA vaccine for Zika virus.

Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS.

Science. 2016 Oct 14;354(6309):237-240. Epub 2016 Sep 22.

15.

Zika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other Flaviviruses.

Goo L, Dowd KA, Smith AR, Pelc RS, DeMaso CR, Pierson TC.

MBio. 2016 Sep 6;7(5). pii: e01396-16. doi: 10.1128/mBio.01396-16.

16.

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC.

Cell Rep. 2016 Aug 9;16(6):1485-1491. doi: 10.1016/j.celrep.2016.07.049. Epub 2016 Jul 29.

17.

Structural Basis of Zika Virus-Specific Antibody Protection.

Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH.

Cell. 2016 Aug 11;166(4):1016-1027. doi: 10.1016/j.cell.2016.07.020. Epub 2016 Jul 27.

18.

Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Mukherjee S, Sirohi D, Dowd KA, Chen Z, Diamond MS, Kuhn RJ, Pierson TC.

Virology. 2016 Oct;497:33-40. doi: 10.1016/j.virol.2016.06.022. Epub 2016 Jul 13.

19.

A CRISPR screen defines a signal peptide processing pathway required by flaviviruses.

Zhang R, Miner JJ, Gorman MJ, Rausch K, Ramage H, White JP, Zuiani A, Zhang P, Fernandez E, Zhang Q, Dowd KA, Pierson TC, Cherry S, Diamond MS.

Nature. 2016 Jul 7;535(7610):164-8. Epub 2016 Jun 17.

20.
21.

Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly.

VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC.

J Virol. 2015 Aug;89(16):8632-42. doi: 10.1128/JVI.01253-15. Epub 2015 Jun 10.

22.

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Kuhn RJ, Dowd KA, Beth Post C, Pierson TC.

Virology. 2015 May;479-480:508-17. doi: 10.1016/j.virol.2015.03.025. Epub 2015 Mar 30. Review.

23.

CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, Thomas DL, Ray SC.

J Infect Dis. 2015 Sep 15;212(6):914-23. doi: 10.1093/infdis/jiv139. Epub 2015 Mar 9.

24.

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.

Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE; VRC 311 Study Team.

Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.

PMID:
25132507
25.

Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition.

Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC.

J Virol. 2014 Oct;88(20):11726-37. doi: 10.1128/JVI.01140-14. Epub 2014 Jul 30.

26.

Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2014 Apr 17;10(4):e1004072. doi: 10.1371/journal.ppat.1004072. eCollection 2014 Apr.

27.

Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC.

J Virol. 2014 Jul;88(13):7210-20. doi: 10.1128/JVI.03690-13. Epub 2014 Apr 16.

28.

Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection.

Mukherjee S, Pierson TC, Dowd KA.

Methods Mol Biol. 2014;1138:75-97. doi: 10.1007/978-1-4939-0348-1_6.

PMID:
24696332
29.

B cell response and mechanisms of antibody protection to West Nile virus.

Austin SK, Dowd KA.

Viruses. 2014 Mar 3;6(3):1015-36. doi: 10.3390/v6031015. Review.

30.

The Rockefeller University Navigation Program: a structured multidisciplinary protocol development and educational program to advance translational research.

Brassil D, Kost RG, Dowd KA, Hurley AM, Rainer TL, Coller BS.

Clin Transl Sci. 2014 Feb;7(1):12-9. doi: 10.1111/cts.12134. Epub 2014 Jan 9.

31.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

32.

The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.

33.

Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS.

PLoS Pathog. 2013;9(4):e1003312. doi: 10.1371/journal.ppat.1003312. Epub 2013 Apr 18.

34.

Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses.

Obara CJ, Dowd KA, Ledgerwood JE, Pierson TC.

Virology. 2013 Mar 1;437(1):20-7. doi: 10.1016/j.virol.2012.11.016. Epub 2013 Jan 10.

35.

Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope.

Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2012;8(10):e1002930. doi: 10.1371/journal.ppat.1002930. Epub 2012 Oct 4.

36.

Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Shrestha B, Austin SK, Dowd KA, Prasad AN, Youn S, Pierson TC, Fremont DH, Ebel GD, Diamond MS.

Virology. 2012 Jun 5;427(2):127-34. doi: 10.1016/j.virol.2012.02.010. Epub 2012 Mar 9.

37.

A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus.

Lin TY, Dowd KA, Manhart CJ, Nelson S, Whitehead SS, Pierson TC.

J Virol. 2012 Apr;86(7):3501-12. doi: 10.1128/JVI.06435-11. Epub 2012 Jan 18.

38.

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS.

J Virol. 2011 Nov;85(22):11567-80. doi: 10.1128/JVI.05859-11. Epub 2011 Sep 14.

39.

The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases.

Mukherjee S, Lin TY, Dowd KA, Manhart CJ, Pierson TC.

J Virol. 2011 Nov;85(22):12067-72. doi: 10.1128/JVI.05559-11. Epub 2011 Aug 31.

40.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

41.

Antibody-mediated neutralization of flaviviruses: a reductionist view.

Dowd KA, Pierson TC.

Virology. 2011 Mar 15;411(2):306-15. doi: 10.1016/j.virol.2010.12.020. Epub 2011 Jan 20. Review.

42.

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.

43.

Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.

Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC.

J Virol. 2010 May;84(10):5067-77. doi: 10.1128/JVI.02265-09. Epub 2010 Mar 3.

44.

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, Thomas DL, Cox AL.

Gastroenterology. 2010 Jan;138(1):315-24. doi: 10.1053/j.gastro.2009.09.017. Epub 2009 Sep 24.

45.

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC.

Gastroenterology. 2009 Jun;136(7):2377-86. doi: 10.1053/j.gastro.2009.02.080. Epub 2009 Mar 17.

46.

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, Clute S, Wang C, Korman A, Sette A, Sidney J, Pardoll DM, Cox AL.

J Immunol. 2008 Dec 15;181(12):8215-25.

47.

Maternal neutralizing antibody and transmission of hepatitis C virus to infants.

Dowd KA, Hershow RC, Yawetz S, Larussa P, Diaz C, Landesman SH, Paul ME, Read JS, Lu M, Thomas DL, Netski DM, Ray SC.

J Infect Dis. 2008 Dec 1;198(11):1651-5. doi: 10.1086/593067.

48.

Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin.

Geisbrecht BV, Dowd KA, Barfield RW, Longo PA, Leahy DJ.

J Biol Chem. 2003 Aug 29;278(35):32561-8. Epub 2003 Jun 16.

Supplemental Content

Support Center